Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
June 30, 2021
Plasma ACE2 species are differentially altered in COVID-19 patients
María-Salud García-Ayllón, Oscar Moreno-Pérez, Juan García-Arriaza, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|
April 1, 2023
Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment
Héctor Pinargote-Celorio, Silvia Otero-Rodríguez, Pilar González-de-la-Aleja, et al.
Journal of the International AIDS Society
|
November 14, 2014
The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
Enrique Ortega Gonzalez, Vicente Boix, Miguel Garcia Deltoro, et al.
Microorganisms
|
August 27, 2021
Latin American Origin Is Not Associated with Worse Outcomes among Hospitalized Patients with COVID-19 in a Public Healthcare System
Silvia Otero-Rodriguez, Oscar Moreno-Pérez, Jose Manuel Ramos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 25, 2008
Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy
Juan Berenguer, Pilar Miralles, José María Ribera, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Juan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]
Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
The Journal of Antimicrobial Chemotherapy
|
October 6, 2019
Factors associated with the number of drugs in darunavir/cobicistat regimens
Esteban Martinez, Eugenia Negredo, Hernando Knobel, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]
Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
Plos One
|
February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Jesús Troya, Pablo Ryan, Esteban Ribera, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
June 30, 2021
Plasma ACE2 species are differentially altered in COVID-19 patients
María-Salud García-Ayllón, Oscar Moreno-Pérez, Juan García-Arriaza, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|
April 1, 2023
Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment
Héctor Pinargote-Celorio, Silvia Otero-Rodríguez, Pilar González-de-la-Aleja, et al.
Journal of the International AIDS Society
|
November 14, 2014
The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
Enrique Ortega Gonzalez, Vicente Boix, Miguel Garcia Deltoro, et al.
Microorganisms
|
August 27, 2021
Latin American Origin Is Not Associated with Worse Outcomes among Hospitalized Patients with COVID-19 in a Public Healthcare System
Silvia Otero-Rodriguez, Oscar Moreno-Pérez, Jose Manuel Ramos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 25, 2008
Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy
Juan Berenguer, Pilar Miralles, José María Ribera, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Juan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]
Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
The Journal of Antimicrobial Chemotherapy
|
October 6, 2019
Factors associated with the number of drugs in darunavir/cobicistat regimens
Esteban Martinez, Eugenia Negredo, Hernando Knobel, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]
Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
Plos One
|
February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Jesús Troya, Pablo Ryan, Esteban Ribera, et al.
Page
of 7